Strategic options Selvita has just launched a strategic options review alongside reporting Q1 2026 results, signaling openness to partnership, collaboration, or restructuring that could create near-term selling opportunities in drug discovery programs, outsourcing pipelines, or strategic investments.

Preclinical leadership As one of Europe’s largest preclinical contract research organizations, Selvita presents a strong partner of choice for biotech and pharma seeking to accelerate early drug discovery and bridging to clinical development in a context of growing CRO demand.

Financial scale With reported Q1 results and a revenue range in the mid tens of millions, Selvita’s size and growth trajectory position it to pursue larger, multi-year collaborations or expanded scope projects with mid to large biopharma clients.

Quality and tech A diverse tech stack and ISO focus indicate a commitment to quality, repeatability, and compliance, which can be leveraged to sell integrated services such as data-driven discovery, translational analytics, and secure CRO platforms.

European access Being a prominent European CRO with multinational exposure and connections to Western markets, Selvita offers cross-border collaboration opportunities, potential co-development deals, and regional partnerships for clients expanding in Europe and neighboring regions.